Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine after Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)

AIDS Research and Human Retroviruses

Volumn 32, Issue 1, 2016, Pages 32-43

  Hendrix, Craig W ^a   Andrade, Adriana ^a   Bumpus, Namandjé N ^a   Kashuba, Angela D ^b   Marzinke, Mark A ^a   Moore, Ayana ^c   Anderson, Peter L ^d   Bushman, Lane R ^d   Fuchs, Edward J ^a   Wiggins, Ilene ^a   Radebaugh, Christine ^a   Prince, Heather A ^b   Bakshi, Rahul P ^a   Wang, Ruili ^b   Richardson, Paul ^a   Shieh, Eugenie ^a   McKinstry, Laura ^e   Li, Xin ^e   Donnell, Deborah ^e   Elharrar, Vanessa ^f   Mayer, Kenneth H ^g   Patterson, Kristine B ^b   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c FAMILY HEALTH INTERNATIONAL   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e SCHARP   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g FENWAY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EMTRICITABINE; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

ADULT; ARTICLE; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NORMAL HUMAN; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEMEN ANALYSIS; TREATMENT DURATION; BENCHMARKING; BLOOD; BODY FLUID; CHEMISTRY; DRUG ADMINISTRATION; PRE-EXPOSURE PROPHYLAXIS; RECEIVER OPERATING CHARACTERISTIC; STATISTICS AND NUMERICAL DATA; TABLET;

ADULT; ANTI-HIV AGENTS; BENCHMARKING; BODY FLUIDS; DRUG ADMINISTRATION SCHEDULE; EMTRICITABINE; FEMALE; HEALTHY VOLUNTEERS; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; ROC CURVE; TABLETS; TENOFOVIR;

EID: 84954149594     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0182     Document Type: Article

References (36)

1. Baeten JM, Donnell D, Ndase P, et al. : Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410
2. Grant RM, Lama JR, Anderson PL, et al. : Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599
3. Choopanya K, Martin M, Suntharasamai P, et al. : Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. : Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367: 423-434
5. Marrazzo JM, Ramjee G, Richardson B, et al. : Preexposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). New Engl J Med 2015; 372:509-518
6. Van Damme L, Corneli A, Ahmed K, et al. : Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-422
7. Hendrix CW: Exploring concentration response in HIV preexposure prophylaxis to optimize clinical care and trial design. Cell 2013;155:515-518
8. Donnell D, Baeten JM, Bumpus NN, et al. : HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014;66:340-348
9. Karim SS, Kashuba AD, Werner L, and Karim QA: Drug concentrations after topical and oral antiretroviral preexposure prophylaxis: Implications for HIV prevention in women. Lancet 2011;378:279-281
10. Agot K, Taylor D, Corneli AL, et al. : Accuracy of selfreport and pill-count measures of adherence in the FEMPrEP clinical trial: Implications for future HIV-prevention trials. AIDS Behav 2015;19:743-751
11. van der Straten A, Montgomery ET, Hartmann M, and Minnis A: Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep 2013;10:89-102
12. Chaturvedula A, Fossler MJ, and Hendrix CW: Estimation of tenofovirs population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. J Clin Pharmacol 2014;54:150-160
13. Barditch-Crovo P, Deeks SG, Collier A, et al. : Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45:2733-2739
14. Gish RG, Leung NW, Wright TL, et al. : Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002;46:1734-1740
15. Pruvost A, Negredo E, Benech H, et al. : Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005;49:1907-1914
16. Pruvost A, Negredo E, Theodoro F, et al. : Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): Investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother 2009;53:1937-1943
17. Hawkins T, Veikley W, St Claire RL, 3rd, et al. : Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005;39:406-411
18. Adams JL, Patterson KB, Prince HM, et al. : Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women. Antivir Ther 2013;18: 1005-1013
19. Schwartz JL, Rountree W, Kashuba AD, et al. : A multicompartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011;6:e25974
20. Louissaint NA, Cao YJ, Skipper PL, et al. : Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses 2013;29:1443-1450
21. Keller MJ, Madan RP, Torres NM, et al. : A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 2011;6:e16475
22. Bushman LR, Kiser JJ, Rower JE, et al. : Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LCMS/ MS detection. J Pharm Biomed Anal 2011;56:390-401
23. Hendrix CW, Chen BA, Guddera V, et al. : MTN-001: Randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 2013;8:e55013
24. DiFrancesco R, Taylor CR, Rosenkranz SL, et al. : Adding value to antiretroviral proficiency testing. Bioanalysis 2014; 6:2721-2732
25. Chen J, Flexner C, Liberman RG, et al. : Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J Acquir Immune Defic Syndr 2012;61:593-599
26. Burns RN, Hendrix CW, Fossler MJ, and Chaturvedula A: Population pharmacokinetics of tenofovir and tenofovirdiphosphate in healthy women. J Clin Pharmacol 2015;55: 629-638
27. Podsadecki TJ, Vrijens BC, Tousset EP, et al. : White coat compliance limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 2008; 9:238-246
28. Jackson A, Moyle G, Watson V, et al. : Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: Implications for HIV treatment and prevention. J Acquir Immune Defic Syndr 2013;62:275-281
29. Anderson PL, Glidden DV, Liu A, et al. : Emtricitabinetenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012;4:151ra125
30. Seifert SM, GliddenDV, MeditzAL, et al. : Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis 2015;60:804-810
31. Adams JL, Sykes C, Menezes P, et al. : Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: A new measure of antiretroviral adherence? J Acquir Immune Defic Syndr 2013;62:260-266
32. Kiser JJ, Aquilante CL, Anderson PL, et al. : Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 2008;47:298-303
33. Robbins BL, Wilcox CK, Fridland A, and Rodman J: Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003;23(6):695-701
34. Robbins BL, Srinivas RV, Kim C, et al. : Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother 1998;42(3):612-617
35. Jackson A, Moyle G, Watson V, et al. : Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: Implications for HIV treatment and prevention. J Acquir Immune Defic Syndr 2013;62(3):275-281
36. Patterson KB, Prince HA, Kraft E, et al. : Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re114